A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behçet’s syndrome

Infliximab (IFX) was the first biologic introduced for refractory uveitis treatment in Behçet’s syndrome (BS). However, there have been few reports on the safety and efficacy of IFX monotherapy over follow-up periods of more than 10 years. This retrospective study evaluated the 10-year safety and ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Horiguchi, Noe, Kamoi, Koju, Horie, Shintaro, Iwasaki, Yuko, Kurozumi-Karube, Hisako, Takase, Hiroshi, Ohno-Matsui, Kyoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747559/
https://www.ncbi.nlm.nih.gov/pubmed/33335139
http://dx.doi.org/10.1038/s41598-020-78718-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747559/
https://www.ncbi.nlm.nih.gov/pubmed/33335139
http://dx.doi.org/10.1038/s41598-020-78718-z

Ejemplares similares